Tamiflu and Xofluza use different mechanisms, yet both fail to meaningfully change influenza outcomes for most patients.

Tamiflu has been a cornerstone of influenza treatment for decades, yet growing evidence suggests its benefits are limited and often overstated.

Xofluza is a newer antiviral for influenza, but emerging evidence suggests limited benefit, resistance risks, and reasons for caution.

Adipotide is a unique peptide studied for its ability to selectively destroy fat tissue by targeting its blood supply, not appetite or metabolism.

ACE-031 is a myostatin inhibitor designed to increase muscle mass by blocking negative regulators of muscle growth. Here’s what the science reveals.

PNC-28 is a p53-derived peptide studied for its ability to selectively disrupt cancer cell membranes while sparing healthy tissue.